Amgen Inc. (AMGN)
Amgen Inc. (NASDAQ: AMGN) is an American biotechnology company headquartered in Thousand Oaks, California. It discovers, develops, manufactures, and commercializes medicines for serious diseases, with a focus on oncology, inflammation, cardiovascular and general medicine, and rare diseases. Its major products include Prolia, Repatha, Evenity, Enbrel, Otezla, Blincyto, and Tepezza.
| Ticker | AMGN |
|---|
| Company | Amgen Inc. |
|---|
| Exchange | Nasdaq |
|---|
| Headquarters | THOUSAND OAKS, CA |
|---|
Income statement — period ending 2026-06-30
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $2,446,000,000 |
|---|
| Cost of Goods and Services Sold | $2,811,000,000 |
|---|
| Depreciation, Depletion and Amortization, Nonproduction | $222,000,000 |
|---|
| Earnings Per Share, Basic | 4 USD/shares |
|---|
| Earnings Per Share, Diluted | 4 USD/shares |
|---|
| Gross Profit (derived) | $7,243,000,000 |
|---|
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | $2,768,000,000 |
|---|
| Income Tax Expense (Benefit) | $393,000,000 |
|---|
| Investment Income, Interest | $125,000,000 |
|---|
| Net Income (Loss) Attributable to Parent | $2,375,000,000 |
|---|
| Nonoperating Income (Expense) | -$73,000,000 |
|---|
| Operating Income (Loss) | $3,514,000,000 |
|---|
| Revenue from Contract with Customer, Excluding Assessed Tax | $10,054,000,000 |
|---|
| Selling, General and Administrative Expense | $1,745,000,000 |
|---|
| Share-based Payment Arrangement, Noncash Expense | $240,000,000 |
|---|
| Weighted Average Number of Shares Outstanding, Diluted | 544,000,000 shares |
|---|
| Weighted Average Number of Shares Outstanding, Basic | 540,000,000 shares |
|---|
Sourced from SEC EDGAR/XBRL filings via StockSpectro.
View full interactive research on StockSpectro